Intracellular Angiotensin-II Measurement in Streptozotocin-Induced Rat Vascular Smooth Muscle Cells and Its Relationship with Angiotensin-II Receptors
Methods: VSMCs were isolated from the aorta of healthy and diabetic Wistar rats. Diabetic model was achieved by intravenous administration of 45 mg/kg streptozotocin. Firstly, different Ang-II (0-1000 μM) concentration was performed for dose study. Ang-II (0.1 μM), Ang-II type 1 receptor (ATR1) antagonist (Olmesartan, 1 μM) and Ang-II type 2 receptor (ATR2) antagonist (PD123,319, 1 μM) were practiced together, and thereafter cell proliferation was evaluated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) method. Intracellular and extracellular Ang-II levels were measured by ELISA kit.
Results: While H-VSMCs proliferation increased in Ang-II 0.1, 0.01, 0.001 and 0.0001 μM, D-VSMCs proliferation increased Ang-II 0.1 and 0.01 μM applications (P<0.05). Olmesartan 1 µM inhibited proliferation in H-VSMCs. Ang-II detected intracellular and extracellular groups of VSMCs, but no significant difference was found between H-VSMCs and D-VSMCs groups (P˃0.05).
Conclusions: Ang-II enhances proliferation of H-VSMCs and D-VSMCs. There is no relationship that could be established between intracellular and extracellular Ang-II levels, H-VSMCs and D-VSMCs proliferation and Ang-II receptors.
1. Brown SD, Klimi E, Bakker WAM, Beqqali A, Baker AH. Non-coding RNAs to treat vascular smooth muscle cell dysfunction. Br J Pharmacol. 2025;182(2):246-280. doi: 10.1111/bph.16409.
2. Lee J, Hong SW, Kim MJ, et al. Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification. Diabetes Metab J. 2024;48(1):83-96. doi: 10.4093/dmj.2022.0363.
3. Chi J, Meng L, Pan S, et al. Primary Culture of Rat Aortic Vascular Smooth Muscle Cells: A New Method. Med Sci Monit. 2017;23:4014-4020. doi: 10.12659/msm.902816.
4. Sun Y, Xu H, Xu X, et al. A novel method to obtain rat aortic media for primary culture of rat aortic smooth muscle cells. In Vitro Cell Dev Biol Anim. 2021;57(7):726-734. doi: 10.1007/s11626-021-00615-0.
5. Cao G, Xuan X, Hu J, Zhang R, Jin H, Dong H. How vascular smooth muscle cell phenotype switching contributes to vascular disease. Cell Commun Signal. 2022;20(1):180. doi: 10.1186/s12964-022-00993-2.
6. Grootaert MOJ, Bennett MR. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. Cardiovasc Res. 2021;117(11):2326-2339. doi: 10.1093/cvr/cvab046.
7. Dong LH, Lv P, Han M. Roles of SM22α in cellular plasticity and vascular diseases. Cardiovasc Hematol Disord Drug Targets. 2012;12(2):119-125. doi: 10.2174/1871529x11202020119.
8. Zhang F, Guo X, Xia Y, Mao L. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis. Cell Mol Life Sci. 2021;79(1):6. doi: 10.1007/s00018-021-04079-z.
9. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82-97. doi: 10.1152/ajpcell.00287.2006.
10. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224-236. doi: 10.1111/j.1365-2796.2008.01981.x.
11. Chai W, Danser AH. Is angiotensin II made inside or outside of the cell? Curr Hypertens Rep. 2005;7(2):124-127. doi: 10.1007/s11906-005-0086-0.
12. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52(4):639-672.
13. Martyniak A, Tomasik PJ. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022;13(1):16. doi: 10.3390/diagnostics13010016.
14. Simões E Silva AC, Lanza K, Palmeira VA, Costa LB, Flynn JT. 2020 update on the renin-angiotensin-aldosterone system in pediatric kidney disease and its interactions with coronavirus. Pediatr Nephrol. 2021;36(6):1407-1426. doi: 10.1007/s00467-020-04759-1.
15. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803. doi: 10.1152/physrev.00036.2005.
16. De Mello WC. Intracellular angiotensin II as a regulator of muscle tone in vascular resistance vessels. Pathophysiological implications. Peptides. 2016;78:87-90. doi: 10.1016/j.peptides.2016.02.006.
17. Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiol Rev. 2018;98(3):1627-1738. doi: 10.1152/physrev.00038.2017.
18. Ma J, Li Y, Yang X, et al. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):168. doi: 10.1038/s41392-023-01430-7.
19. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept. 2000;91(1-3):21-27. doi: 10.1016/s0167-0115(00)00136-1.
20. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res. 2002;35(9):1001-1015. doi: 10.1590/s0100-879x2002000900001.
21. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol. 2001;87(8A):25C-32C. doi: 10.1016/s0002-9149(01)01539-9.
22. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab. 2007;18(5):208-214. doi: 10.1016/j.tem.2007.05.001.
23. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93(1-3):65-77. doi: 10.1016/s0167-0115(00)00178-6.
24. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904-92. doi: 10.1161/01.cir.103.6.904.
25. Natarajan R, Scott S, Bai W, Yerneni KK, Nadler J. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension. 1999;33(1 Pt 2):378-384. doi: 10.1161/01.hyp.33.1.378.
26. Ziaja M, Urbanek KA, Kowalska K, Piastowska-Ciesielska AW. Angiotensin II and Angiotensin Receptors 1 and 2-Multifunctional System in Cells Biology, What Do We Know? Cells. 2021;10(2):381. doi: 10.3390/cells10020381.
27. Todd ME, Laye CG, Osborne DN. The dimensional characteristics of smooth muscle in rat blood vessels. A computer-assisted analysis. Circ Res. 1983;53(3):319-331. doi: 10.1161/01.res.53.3.319.
28. Xu S, Fu J, Chen J, et al. Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas. Cytotechnology. 2009;61(1-2):65-72. doi: 10.1007/s10616-009-9236-6.
29. Waterborg JH, Matthews HR. The Lowry method for protein quantitation. Methods Mol Biol. 1994;32:1-4. doi: 10.1385/0-89603-268-X:1.
30. Villar-Cheda B, Costa-Besada MA, Valenzuela R, Perez-Costas E, Melendez-Ferro M, Labandeira-Garcia JL. The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system. Cell Death Dis. 2017;8(9):e3044. doi: 10.1038/cddis.2017.439.
31. Wang K, Deng X, Shen Z, et al. High glucose promotes vascular smooth muscle cell proliferation by upregulating proto-oncogene serine/threonine-protein kinase Pim-1 expression. Oncotarget. 2017;8(51):88320-88331. doi: 10.18632/oncotarget.19368.
32. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989;13(4):305-314. doi: 10.1161/01.hyp.13.4.305.
33. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002;82(6):747-756. doi: 10.1097/01.lab.0000017372.76297.eb.
34. Tambelline N, Oliveira K, Olchanheski Junior LR, et al. The effect of losartan on angiotensin II-induced cell proliferation in a rat aorta smooth muscle cell line. Braz Arch Biol Technol. 2012;55(2):263-268. doi: 10.1590/S1516-89132012000200012.
35. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ. Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension. 1999;33(4):1013-1019. doi: 10.1161/01.hyp.33.4.1013.
36. Igarashi M, Hirata A, Nozaki H, Kadomoto-Antsuki Y, Tominaga M. Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Diabetes Res Clin Pract. 2007;75(3):267-277. doi: 10.1016/j.diabres.2006.06.032.
37. Kyotani Y, Zhao J, Tomita S, et al. Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways. J Pharmacol Sci. 2010;113(2):161-8. doi: 10.1254/jphs.09332fp.
38. Wilson DP, Saward L, Zahradka P, Cheung PK. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res. 1999;42(3):761-772. doi: 10.1016/s0008-6363(98)00340-x.
39. Catt KJ, Cain MC. Measurement of angiotensin II in blood. Lancet. 1967;2(7524):1005-1007. doi: 10.1016/s0140-6736(67)90285-1.
40. Boyd GW, Landon J, Peart WS. Radioimmunoassay for determining plasms-levels of angiotensin II in man. Lancet. 1967;2(7524):1002-1005. doi: 10.1016/s0140-6736(67)90284-x.
41. Gocke DJ, Sherwood LM, Oppenhoff I, Gerten J, Laragh JH. Measurement of plasma angiotensin II and correlation with renin activity. J Clin Endocrinol Metab. 1968;28(11):1675-1678. doi: 10.1210/jcem-28-11-1675.
42. Catt KJ, Cain MD, Zimmet PZ, Cran E. Blood angiotensin II levels of normal and hypertensive subjects. Br Med J. 1969;1(5647):819-821. doi: 10.1136/bmj.1.5647.819.
43. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension. 1991;18(6):763-773. doi: 10.1161/01.hyp.18.6.763.
Copyright (c) 2026 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Article Information
- Article Type Research Article
- Submitted February 21, 2026
- Published April 1, 2026
- Issue Volume 12 - Issue 4 (April 2026)
- Section Research Article
